• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ipsen S.A. ADR (OP: IPSEY )

    31.13 +0.29 (+0.94%)
    Streaming Delayed Price Updated: 1:30 PM EDT, Oct 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Ipsen S.A. ADR

    < Previous 1 2 Next >
    Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
    In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
    The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
    Via Benzinga
    Exposures Product Safety
    3 Promising Biotech Stocks Flying Under the Radar
    Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
    Via InvestorPlace
    Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
    Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
    Via Benzinga
    Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
    Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
    Via Benzinga
    Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
    Via Benzinga
    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
    Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)  
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
    Via Benzinga
    Why These Two Biotech Stocks Blasted Higher This Week
    There's nothing like a big-premium buyout to send a company's share price to the moon. 
    Via The Motley Fool
    2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
    The market is moving higher, and these small companies are helping. 
    Via The Motley Fool
    France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
    Via Benzinga
    Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
    Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
    Via Benzinga
    Why Merrimack Shares Are Surging Over 200% Today?
    Via Benzinga
    Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
    October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
    Via Benzinga
    AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
    Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
    Via Benzinga
    Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
    Via Benzinga
    This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
    Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
    Via Benzinga
    Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
    Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. 
    Via Benzinga
    The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
    Ipsen SA (OTC: IPSEY) has 
    Via Benzinga
    The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
    Via Benzinga
    EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
    Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have  
    Via Benzinga
    Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
    Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
    Via Benzinga
    A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
    Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
    Via Benzinga
    Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
    Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... 
    Via Benzinga
    GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters
    Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! 
    Via InvestorPlace
    Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
    Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... 
    Via Benzinga
    Ipsen Stock Declines After Pulling Rare Disease Application
    Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.